Jack W. Callicutt, chief financial officer of Galectin Therapeutics (GALT), has been a consistent seller of the company’s stock over the past several months, with no open-market purchases recorded in his recent Form 4 filings. Across 41 total transactions, all of his disclosed activity in the single holding has been on the sell side, totaling roughly $998,050 in value. The most recent cluster of sales occurred in early January 2026, with three open-market dispositions on Jan. 2, Jan. 5, and Jan. 6 worth $58,394, $100,298, and $74,695, respectively. Those followed a heavier stretch in mid-November 2025, when Callicutt executed multiple sales on Nov. 10, Nov. 17, and Nov. 18, including a single-day total of nearly $288,000 on Nov. 18 alone.
The pattern is dominated by option exercises paired with same-day sales, a structure that typically reflects a cashless exercise rather than a discretionary bet against the stock. For example, on Nov. 18, Callicutt exercised options valued at $20,213 and $55,638 while simultaneously selling shares worth $113,321 and $174,866. Similar pairings appear on Nov. 10 and Nov. 17, where small option exercises preceded or coincided with sales of $10,000 to $118,000. The two most recent transactions on Jan. 16, 2026, were compensation-related grants (code "A") with no dollar value, which do not alter the overall selling bias.
Notably, Callicutt has not reported a single open-market purchase (code "P") in the dataset, and his recent activity includes 11 sales against zero buys. The absence of acquisitions, combined with the steady stream of sales tied to option exercises, points to a liquidation posture rather than accumulation. While the dollar figures are modest relative to large-cap insider activity, the direction is unambiguous: every discretionary transaction in GALT over this period has been a sale, with the most recent open-market disposition occurring just days before the January grants.
AI-assisted summary